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A hallmark of retroviral replication is integration of
the viral genome into host cell DNA. This character-
istic makes retrovirus-based vectors attractive de-
livery vehicles for gene therapy. However, adverse
events in gene therapeutic trials, caused by activa-
tion of proto-oncogenes due to murine leukemia
virus (MLV)-derived vector integration, hamper their
application. Here, we show that bromodomain and
extraterminal (BET) proteins (BRD2, BRD3, and
BRD4) and MLV integrase specifically interact
and colocalize within the nucleus of the cell. Inhibi-
tion of the BET proteins’ chromatin interaction via
specific bromodomain inhibitors blocks MLV virus
replication at the integration step. MLV integration
site distribution parallels the chromatin binding
profile of BET proteins, and expression of an artifi-
cial fusion protein of the BET integrase binding
domain with the chromatin interaction domain of
the lentiviral targeting factor LEDGF/p75 retargets
MLV integration away from transcription start sites
and into the body of actively transcribed genes,
conforming to the HIV integration pattern. Together,
these data validate BET proteins as MLV integration
targeting factors.INTRODUCTION
Integration of a DNA copy of the retroviral RNA genome into the
host chromatin is a pivotal step in retroviral replication and links
the fate of the invading virus with that of the infected cell. This
characteristic makes retrovirus-based vectors suitable to deliver886 Cell Reports 5, 886–894, November 27, 2013 ª2013 The Authorstherapeutic genes into cells to correct genetic diseases. Murine
leukemia virus (MLV)-derived vectors have been used success-
fully to correct primary immunodeficiency disorders like X-linked
severe combined immunodeficiency (X-SCID) (Cavazzana-
Calvo et al., 2000; Gaspar et al., 2004; Hacein-Bey-Abina
et al., 2002). However, their use led to adverse events in a subset
of patients due to long-terminal-repeat-driven activation of
proto-oncogenes (i.e., insertional mutagenesis) resulting in un-
controlled clonal cell proliferation and leukemia (Deichmann
et al., 2007). Retroviral integration site distribution is not random.
Whereas the host protein lens epithelium-derived growth factor
(LEDGF/p75) targets lentiviral (e.g., HIV) integration toward the
body of active transcription units (Ciuffi et al., 2005), gammare-
troviral (e.g., MLV) integration is independent of LEDGF/p75
and preferentially occurs near transcription start sites (TSSs),
CpG islands, and DNase I-hypersensitive sites (DHSs) (Cattoglio
et al., 2010; Felice et al., 2009; Mitchell et al., 2004; Wu et al.,
2003). In addition, retroviral integration is favored on the out-
ward-facing major groove of nucleosome-wrapped DNA (Roth
et al., 2011; Wang et al., 2007, 2009). It is generally accepted
that cellular proteins, cofactors, dictate target site selection. In
this study, we identified the cellular determinants that target
MLV integration. In earlier work with hybrid HIV viruses, it was
shown that transferring the MLV integrase (IN) coding region
into HIV caused the chimeras to integrate with a specificity close
to that of MLV, revealing IN as the principal viral determinant of
integration specificity (Lewinski et al., 2006). Therefore, we
screened for cellular MLV IN interaction partners that could act
as a MLV-specific tether. Although an earlier study picked up
BRD2 as a MLV IN-interacting protein (Studamire and Goff,
2008), we show here that members of the bromodomain and ex-
traterminal domain containing (BET) family of proteins (BRD2,
BRD3, and BRD4) interact withMLV IN and orchestrate gammar-
etroviral integration, in agreement with a recent report by Sharma
et al. (2013) and that engineered BET proteins can retarget MLV
replication.
Figure 1. BET Proteins Interact with MLV IN
and Are Important for Viral Integration
(A) Schematic representation of human/murine
BET proteins. Numbers correspond to aa
positions. BD, bromodomain; ET, extraterminal
domain; SEED, serine, glutamic acid, aspartic
acid-rich domain.
(B) Coimmunoprecipitation of endogenous BRD4
from 293T cells expressing flag-tagged MLV IN
analyzed by western blot.
(C) 293T cells were cotransfected with flag-tagged
MLV IN and eGFP-mBRD2, eGFP-mBRD3, or
eGFP-mBRD4 expression constructs. MLV
IN (Flag-IP) or mBRD proteins (eGFP-IP) were
precipitated and analyzed by western blot.
(D and E) NIH 3T3 cells were transduced with
MLV-derived vectors (MLV-Fluc) (D) or infected
with an eGFP expressing viral clone (MLV-eGFP
virus) (E) in the presence of 200 nM JQ1() or
JQ1(+), 500 nM I-BET, or an equivalent amount of
DMSO as a negative control. Two multiplicities of
infection (MOI) are presented. Twenty-four hours
after transduction/infection, cells were washed,
and, in case of the viral clone, raltegravir (1 mM)
was added to prevent multiple-round replication.
Twenty-four hours later, transduction or infection
efficiency was determined. Data are plotted as
average ±SD of triplicate measurements.
(F) NIH 3T3 cells were infected with MLV-eGFP as
in (E). Subsequently, cells were expanded and split
until 10 days after infection. The number of inte-
grated copies was determined via qPCR and
normalized to GADPH. Average values and SDs of
a triplicate measurement are shown.
In all panels, differences were determined using a
Student’s t test. *p < 0.05, **p < 0.01, ***p < 0.001.RESULTS
BET Proteins Bind MLV Integrase
We singled outMLV integrase (IN)-interacting proteins from 293T
cell extracts expressing triple flag-taggedMLV IN via coimmuno-
precipitation (coIP) of IN using flag-affinity matrix. Eluted pro-
teins were identified by mass spectrometry (MS). Wild-type
293T cells were analyzed in parallel as control. Bromodomain
containing protein 4 (BRD4) was represented with the largest
set of peptides (data not shown), but we also identified BRD3.
Of note, an earlier study picked up BRD2 as an MLV IN-interact-
ing protein (Studamire and Goff, 2008). All these proteins are
members of the bromodomain and extraterminal (BET) protein
family (Figure 1A) and share two chromatin-interacting bromo-
domains, recognizing acetylated histone tails, and a protein-
interacting extraterminal (ET) domain (for a review, see Devaiah
and Singer, 2013). To confirm the interaction of endogenous
BRD4 with MLV IN, transiently expressed flag-tagged MLV IN
was immunoprecipitated from 293T nuclear extracts. BRD4
was readily detected in the pull-down fraction by western blot
(Figure 1B). In addition, 3xflag MLV IN interacted with bothCell Reports 5, 886–894, Nhuman and mouse BRD4 (hBRD4 and
mBRD4) (coIP, data not shown). A similar
coIP experiment in cells transiently ex-pressing eGFP-tagged BET proteins and flag-tagged MLV IN
showed that, next to eGFP-mBRD4, MLV IN interacts with
eGFP-taggedmBRD2 andmBRD3 as well (Figure 1C). When ex-
pressed alone, eGFP-tagged BET proteins located in the nu-
cleus of NIH 3T3 cells, whereas MLV IN fused to the monomeric
red fluorescent protein (mRFP-MLV IN) predominantly located to
the cytoplasm with only trace amounts in the nucleus (Fig-
ure S1A). However, coexpression of mBRD2, -3, or -4 with
mRFP-MLV IN relocatedMLV IN to the nucleus of the cell, coloc-
alizing with the respective BET proteins (Figures S1A and S1B).
Similar data were obtained in HeLa cells (data not shown).
Bromodomain Inhibitors Reduce MLV Replication
To evaluate the role of BET proteins in MLV replication, we ex-
ploited the recently identified BET protein bromodomain inhibi-
tors JQ1(+) and I-BET (Filippakopoulos et al., 2010; Nicodeme
et al., 2010). JQ1() (the inactive R-enantiomer) and DMSO
served as negative controls. Based on 50% cytotoxicity (CC50)
and inhibitory concentrations (IC50) (Table S1), we used JQ1(+)
and I-BET concentrations of 200 and 500 nM, respectively.
NIH 3T3 cells were either transduced with a retroviral vectorovember 27, 2013 ª2013 The Authors 887
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encoding firefly luciferase (MLV-Fluc vector) (Figure 1D) or
infected with a viral clone expressing eGFP (MLV-eGFP virus)
(Figure 1E). Both vector transduction and virus infection were
inhibited 5- to 10-fold compared to JQ1() or DMSO control,
respectively, whereas transduction with an HIV-derived vector
(HIV-Fluc) was not inhibited (Figure S1C). Similar results were
obtained in HeLa cells using the MLV-Fluc vector (data not
shown). Reporter gene expression following transfection of
the MLV-eGFP molecular clone was not affected by the
presence of JQ1(+) or I-BET excluding transcriptional effects
(Figure S1D). To determine the step in the viral replication cycle
where bromodomain inhibitors inhibit MLV replication, viral DNA
intermediates were measured via quantitative PCR (qPCR).
Quantification of the integrated proviral copies at 10 days post-
transduction/infection in the presence of BET inhibitors revealed
that the integrated MLV (virus or vector) copies were reduced
2- to 3-fold, whereas HIV-Fluc integration was not inhibited (Fig-
ures 1F, S1E, and S1F, for MLV-eGFP virus, MLV-Fluc vector,
and HIV-Fluc, respectively). Because the amount of total DNA
at early time points after infection, which is a measure of reverse
transcription, was not reduced in the presence of BET inhibitors
(Figure S1G), we conclude that BET proteins act at a step
between reverse transcription and integration.
The MLV IN C Terminus Binds the BET Extraterminal
Domain
Pull-down experiments using a panel of eGFP-tagged mBRD4
truncation mutants pinpointed the ET domain (BRD4ET, aa 601–
685) as the minimal IN binding domain (Figures S2A and S2B).
Confocal microscopy experiments corroborated that BRD4ET is
the minimal domain required for colocalization with mRFP-MLV
IN (Figure S2C; data not shown). Recombinant glutathione-S-
transferase (GST)-tagged BRD4ET and BRD4ETSEED (aa 601–
721) and His6-tagged MLV IN were shown to interact in an
AlphaScreen protein-protein interaction assay (apparent Kd of
58.70 ± 8.05 nM and 8.56 ± 1.55 nM respectively), confirming a
direct interaction (Figure 2A). As expected, recombinant BRD2ET
and BRD3ET interacted with MLV IN as well, with Kd values in the
same range asBRD4ET (Figure 2B). Considering the conservation
in the ET domain among BET proteins (Figure 2C) and the
BRD4ET NMR structure (Lin et al., 2008), we introduced E652Q,Figure 2. The BET Protein ET Domain Interacts with the MLV IN C Term
(A) Direct interaction of His6-tagged MLV IN (80 nM) with an increasing amount of
by AlphaScreen. Apparent Kds of 8.56 ± 1.50 nM (ETSEED) and 58.70 ± 8.05 nM (
(B) Comparable affinity of different BET proteins for MLV IN. His6-taggedMLV IN (4
of 0.60 ± 0.17, 0.97 ± 0.18, and 0.41 ± 0.03 nM were determined for MBP-BRD2
(C) Sequence alignment (ClustalW) of the ET domain of mBRD4 (Q9ESU6, aa 601
(Q91Y44, aa 496–578), Saccharomyces cerevisiae (Sc) Bromodomain factor (Bd
Homeotic (Fs[1]h) (P13709, aa 942–1024).
(D) NMR structure of the ET domain of BRD4 (Lin et al., 2008).
(E) Interaction of His6-tagged MLV IN (80 nM) with GST-tagged mBRD4601685 m
(F) Coimmunoprecipitation of endogenous BRD4 with flag-tagged MLV, HIV, or R
(G) Interaction of 10 nMMBP-tagged mBRD4ET with His6-tagged MLV, HIV, RSV,
determined using a nonlinear regression curve fit for specific binding. The other
(H) Interaction of 80 nMHis-taggedmBRD4ETwith increasing amounts of theGST-
as measured by AlphaScreen.
(I) Interaction of 80 nMHis-taggedmBRD4ET with GST-taggedMLV IN, the indicat
mutation as measured by AlphaScreen. All AlphaScreen experiments were perfo
Representative experiments are shown. Error bars indicate the SDs of triplicate
CeE654Q, D656N, and E658Q mutations in the BRD4 ET domain
(Figure 2D). Maximal loss of binding was obtained with the
quadruple mutant (referred to as BRD4ETmut in further experi-
ments) (Figure 2E). The observed interaction with BET proteins
was specific forMLV IN, because IN proteins fromother retroviral
families did not interact with BET proteins as revealed by coIP
using lysates of 293T cells transiently expressing flag-tagged
MLV, HIV, or RSV (Rous Sarcoma Virus) IN (Figure 2F). Similar
datawere obtained in an AlphaScreen assaymeasuring the inter-
action of maltose-binding protein (MBP)-tagged BRD4ET with
His-tagged MLV, HIV, RSV, or PFV (Prototype Foamy Virus) IN
(Figure 2G). To pinpoint the MLV IN-BET interacting domain,
different flag-tagged MLV IN deletion constructs were gener-
ated, transiently expressed in 293T cells, and tested by coIP (Fig-
ure S2D). Only MLV IN fragments containing the C-terminal
domain (MLV IN270409) pulled down endogenous BRD4 from
293T cell lysates. Specific interaction in cells was corroborated
by colocalization of the mRFP-MLV IN270409 and eGFP-tagged
mBRD4 using confocal microscopy (Figure S2E). AlphaScreen
analysis using smaller truncation mutants of the MLV IN C-termi-
nal domain revealed that the last 27 residues of MLV IN (aa 382–
409) were sufficient to interact with BRD4ET (Figure 2H). Finally,
alanine scanning of the latter domain revealed W391 to be criti-
cally important for the interaction (Figure 2I; data not shown).
Similar results were obtained for BRD2ET and BRD3ET (data not
shown). Taking into account that BET proteins are known to
associate with promoter regions through their bromodomains
(Leroy et al., 2012) and interact with MLV IN through their ET
domain in a gammaretrovirus-specific manner, we considered
BET proteins as good candidate MLV targeting factors.
MLV Vectors Integrate near BET Protein Hot Spots
To correlate MLV integration with BET-chromatin binding sites,
we determined 10,514 unique MLV vector integration sites in
293T cells and computationally generated matched random
control (MRC) sites. Integration sites were compared with the
BRD2, -3, and -4 chromatin binding profile (Table S2) (Leroy
et al., 2012). HOX gene clusters are enriched for BRD2–4-bound
nucleosomes (Leroy et al., 2012). Indeed, we detected 11, 10,
and 23 MLV integration sites in the HOXA, HOXB (data not
shown), and HOXC (Figure 3A) clusters, respectively, versus 1,inus
GST-tagged mBRD4ET, GST-tagged mBRD4ETSEED or GST alone as measured
ET) were determined using a nonlinear regression curve fit for specific binding.
0 nM) was titrated against the indicatedMBP-fused ET domains. Apparent Kds
, -3, and -4, respectively. MBP-LEDGF325530 was used as a negative control.
–683), mBRD3 (Q8K2F0, aa 563–645), mBRD2 (Q7JJ13, aa 630–712), mBRDT
f1) (P35817, aa 518–598), and Drosophila melanogaster (Dm) Female Sterile
utants as measured by AlphaScreen.
SV IN analyzed by western blot.
or PFV IN measured by AlphaScreen. The Kd for MLV IN (56.7 ± 23.08 nM) was
INs showed no binding to BRD4601721.
taggedMLV INC-terminal domain (aa 270–409) and truncationmutants thereof
ed C-terminal MLV-IN deletion mutant (aa 1–381) or MLV INwith aW391A point
rmed three times.
data points.
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Figure 3. MLV Vectors Integrate in BET Protein Hot Spots
(A) Schematic representation of the BET chromatin binding profile (Leroy et al., 2012) and MLV integration sites (MLV) in theHOXC cluster in 293T cells. Matched
random control (MRC) sites were absent in this region.
(B) Receiver-operator characteristic (ROC) analysis of BRD2–4, Pol II, H3K4me3, and CpG islands (Berry et al., 2006). The area under the curve (AUC) is calculated
for the different markers and shown in Table S3.
(C–G) Mean background-subtracted sequencing read density in 50 bp bins in a 10 kb window around (C and D) TSSs or (E–G) MLV integration sites. ChIP-seq
read density for (C and E) BRD2–4 and (D and F) the unrelated transcription factors PHF8, ELK4, KAP1, and TCF7L2 are plotted on the left y axis. (G) Open
chromatin (DNase I hypersensitvity [DHS]) and Pol II (ChIP-seq) read densities are plotted on the left axis, whereas those frommicrococcal nuclease sequencing
(MN-seq) revealing nucleosome positions are shown on the right axis. In (C–F), the number of MLV andMRC sites is plotted on the right y axis as a fraction of the
total number of respective sites.
(H) ROC analysis of BRD4, Pol II, and CpG islands in primary human CD4+ T cells. Corresponding AUC values are given in Table S3.
(I) Schematic representation of the ITGAL (Integrin alpha-L) locus and the 30 end of the TRB (T cell receptor beta) locus highlighting MLV integration sites, BRD4
peaks, and MRC sites.0, and 0 MRC sites. Genome-wide MLV integration was signifi-
cantly (p < 0.0001, Mann-Whitney U test) enriched in regions
bound by either of the three BET proteins: 42.7%, 23.5%, and890 Cell Reports 5, 886–894, November 27, 2013 ª2013 The Authors15% of integration sites were situated in BRD2, -3, or -4 islands
respectively, compared to 1.9%, 0.9%, and 0.6% of MRC (Table
S3). In addition, we observed stronger correlation with BET
protein binding than with previously described markers associ-
ated with MLV integration such as Pol II binding, H3K4me3, or
CpG islands (9.1, 6.9, 4.4%, respectively) (Table S3) (Cavazza
et al., 2013; Santoni et al., 2010). BRD2 proved to be the best
predictor for MLV integration (Figure 3B), with over 50% of
MLV integration sites locating within 149 bp of a BRD2 binding
site (Table S3). Moreover, both MLV integration sites and
BRD2–4 chromatin immunoprecipitation sequencing (ChIP-
seq) tags concentrate around RefGene TSSs with a similar
bimodal distribution (Figure 3C) (Cattoglio et al., 2010), which dif-
fers from the pattern of other transcription factors defined in
293T cells (KAP1, ELK4, TCF7L2, and PHF8; Table S2; Fig-
ure 3D). Analysis of the distribution of BRD2–4 around MLV inte-
gration sites revealed that the BRD2–4 occupancy is highest at
the integration site itself (Figure 3E), whereas the maximal tag
density for other transcription factors is adjacent to the integra-
tion site (Figure 3F). In addition, we observed a clear peak of
nucleosome occupancy at the site of integration (Figure 3G),
supporting the notion that MLV preferentially integrates into
nucleosomal DNA in vivo (Roth et al., 2011). Indeed, open chro-
matin (Kundaje et al., 2012; Natarajan et al., 2012) and RNA Pol II
are favored at either side of the integration site, in accordance
with the preference for nucleosomal targeting (Figure 3G).
Similar results were obtained when MLV integration sites were
compared to ChIP-seq data for BRD4 in primary human CD4+
T cells (Roth et al., 2011; Zhang et al., 2012). 18.8% of MLV inte-
grations were located in BRD4 islands compared to 0.7% of
MRC sites, 17.0% of Pol II peaks, and 2.3% CpG islands (Table
S3). Receiver-operator characteristic (ROC) analysis confirmed
that MLV integration sites correlate best with the BRD4 chro-
matin binding profile (Figure 3H; Table S3). Analysis of CD4+
T cell-specific loci that are active and bound by BRD4, such as
the ITGAL and the TRB locus, underscored the link between
BET proteins (BRD4) and MLV integration (Figure 3I). The ITGAL
locus (16p11.2), for instance, encodes integrin alpha-L (CD11A)
and contains four BRD4 islands all of which are associated with
MLV integration sites (MLV n = 52; MRC n = 6). A similar pattern
was observed at the 30 end of the T cell receptor beta locus (TRB,
location 7q34) in the joining and constant segment coding region
(MLV n = 33; MRC n = 2).
BRD4 Hybrids Retarget MLV Integration
Taken together, our data are consistent with a role of BET pro-
teins in gammaretroviral integration site targeting. If this is the
case, fusions of the MLV IN-interacting domain with another
chromatin binding domain should redirect integration away
from the MLV-like pattern. To unambiguously prove this hypoth-
esis, we generated NIH 3T3 and SupT1 cell lines stably express-
ing a chimeric fusion protein linking mBRD4ETSEED with the
chromatin binding domain of the lentiviral targeting factor,
LEDGF/p75 (aa 1–324) (LEDGF1324mBRD4ETSEED). As a con-
trol, we also generated cell lines expressing the quadruple-inter-
action-defective mutant (LEDGF1324mBRD4ETSEEDmut). Protein
expression, verified by western blotting, did not affect cell
growth (data not shown). Following transduction with a MLV-
based vector, we amplified MLV integration sites and analyzed
their distribution. In line with an earlier report, MLV integration
in wild-type SupT1 cells was enriched within a 2 kb windowCenear TSSs (22.0%), CpG islands (23.1%), and DNase I-hyper-
sensitive sites (DHSs) (47.7%) (p < 0.001 compared to MRC)
(Figure 4A). Expression of LEDGF1324mBRD4ETSEED shifted
integration away from these features and toward RefSeq genes
(from 49.3% to 58.9%), whereas an intermediate phenotype was
observed for the interaction-deficient mutant. Even more pro-
nounced results were obtained in NIH 3T3 cells (Figure 4A).
When integration sites were binned based on their distance to
TSSs and CpG or DHS islandmidpoints (Figures 4B–4D, respec-
tively), LEDGF1324mBRD4ETSEED overexpression targeted inte-
gration away from the TSS, CpG island, and DHS midpoints
(compare red and green bars), a pattern reminiscent of that of
lentiviral vector integration (purple bars) (Wu et al., 2003). In addi-
tion, when analyzing integration preferences relative to a wide
range of genomic and epigenetic features (Figures 4E and S3),
expression of the LEDGF1324mBRD4ETSEED shifted integration
from aMLV to anHIV-like phenotype for all investigatedmarkers,
in contrast to overexpression of the ETSEED quadruple mutant
protein. Together these data show that overexpression of a
LEDGF1324mBRD4ETSEED fusion protein efficiently shifts the
MLV integration profile, corroborating that BET proteins function
as integration targeting factors for MLV.
DISCUSSION
Although HIV integration site targeting is mediated by LEDGF/
p75 (Cherepanov et al., 2003; Ciuffi et al., 2005; Gijsbers et al.,
2010; Llano et al., 2006; Schrijvers et al., 2012; Shun et al.,
2007), the cellular cofactor driving MLV integration site targeting
remained unknown. Here, we describe BET proteins as the MLV
targeting factors. In agreement with Sharma et al. (2013), we
show that BRD2, BRD3, and BRD4 specifically interact with
MLV IN and that bromodomain inhibitors can block MLV replica-
tion at the integration step. Further, it was shown that a recom-
binant BRD4 deletion mutant containing the bromodomains
and the ET domain stimulated MLV concerted integration
in vitro (Sharma et al., 2013). BET protein knockdown or treat-
ment with JQ1(+) decreases integration around TSSs and CpG
islands (Sharma et al., 2013). In addition, we demonstrate that,
even in the presence of endogenous BET proteins, MLV integra-
tion efficiently shifts toward an HIV phenotype upon expression
of a LEDGF1324mBRD4ETSEED fusion, underscoring the role of
BET proteins in MLV targeting. Retroviruses tend to direct inte-
gration into outward-facing major grooves on nucleosome-
wrapped DNA (Roth et al., 2011). TSSs of expressed genes are
nucleosome depleted, whereas the TSSs of the same genes
when not expressed are nucleosome bound (Struhl and Segal,
2013). Because MLV integrates at TSSs of actively transcribed
genes, the bimodal MLV integration pattern naturally follows.
However, the exact role of BET proteins, known to bind poly-
acetylated histone tails found around TSSs, remains to be
investigated.
The specificity of the interaction of BET proteins for gammare-
troviral IN explains MLV integration site distribution. Lentiviral
(HIV), alpharetroviral (RSV), nor spumaviral (PFV) IN interact with
BET proteins. When and why different retroviral families evolved
to interact with distinct targeting factors and how this relates to
replicationkineticsandpathogenesis remainspoorly understood.ll Reports 5, 886–894, November 27, 2013 ª2013 The Authors 891
Figure 4. A LEDGF-BRD4 Chimeric Protein
Retargets MLV Integration toward an HIV-
like Pattern
(A) MLV or HIV integration sites obtained from
SupT1 or NIH 3T3 cells and their genomic distri-
bution. The percentage of integrations in RefSeq
genes and around TSS, CpG islands, and DNase
I-hypersensitive sites (2 and 4 kb window) is
shown. Matched random control (MRC) sites or
MLV and HIV integration sites in wild-type cells are
shown. TSS, transcription start site; CpG, CpG-
rich island; DNase, DNase I-hypersensitive site.
Asterisks depict pairwise Fisher’s test compared
to MLV-SupT1jHIV-SupT1 *p < 0.05; **p < 0.01;
***p < 0.001. All data reach significance, p < 0.001,
compared to MRC.
(B–D) Integration frequencies surrounding RefSeq
TSSs, CpG islands, and DNase I-hypersensitive
sites in SupT1 cells.
(E) Heatmap of integration frequency relative to
genomic features in SupT1 cells, summarizing the
relation between proviral integration sites and
genomic features. Integration data sets are indi-
cated above the columns. Genomic features
analyzed are shown to the left of the correspond-
ing row of the heatmap. Tile color indicates
whether a particular feature is favored (red) or
disfavored (blue) for integration for the respective
data sets relative to their MRCs, as detailed in the
colored ROC area scale at the bottom of the panel.
p values (asterisks) show significance of de-
partures from the MLV integration sites in WT
SupT1 cells (*p < 0.05; **p < 0.01; ***p < 0.001,
Wald statistics referred to c2 distribution). The
naming of the genomic features is described in
Brady et al. (2009).Our in vitro analysis revealed that the evolutionary conserved
BRD4 ET domain amino acids E652, E654, D656, and E658 are
pivotal for interaction with MLV IN. Still, no interaction was de-
tected between MLV IN and the yeast Bdf1 ET domain, suggest-
ing the existence of other important interaction points (data not
shown). Although LEDGF/p75 binds HIV IN across the catalytic
core domain dimer interface, BET proteins interact with the 27
C-terminal aa of MLV IN. A single point mutant (W391A) is suffi-
cient to abolish this interaction. Future research will show
whether it is possible to replace the BET binding region by alter-892 Cell Reports 5, 886–894, November 27, 2013 ª2013 The Authorsnative chromatin interaction domains,
possibly resulting in a safer retroviral inte-
gration site profile.
In conclusion, we propose a model for
MLV integration targeting incorporating
previous insights on the function of MLV
p12 and the MLV IN-BET interaction (Fig-




The BET compounds JQ1 (Filippakopoulos et al.,
2010) (the active, positive JQ1[+] and inactive,negative JQ1[] enantiomer) and I-BET (Nicodeme et al., 2010) were kindly
provided by J. Bradner (Harvard University) and dissolved in DMSO.
Retroviral Vector Transduction
NIH 3T3 (2 3 104) or SupT1 (8 3 104) cells were seeded in 96-well plates.
After 24 hr, cells were transduced with MLV- or HIV-derived vector particles.
After 48 hr, cells were washed and cultured for another 24 hr in normal growth
medium. Subsequently, cells were split, and 50% was reseeded for luciferase
assays or flow cytometry analysis, whereas the remaining 50% was kept in
culture to determine integrated copies and/or to perform integration site
analysis.
Virus Infection
To monitor early MLV-eGFP replication in the presence/absence of BET inhib-
itors, 2 3 106 NIH 3T3 cells were seeded in a 6-well plate. Twenty-four hours
later, cells were infected with MLV-eGFP at a multiplicity of infection (moi) of
5,000 reverse transcriptase units per well with or without the indicated com-
pounds. Four hours after infection, cells were washed twice with phosphate-
buffered saline (PBS) and fresh medium containing the indicated compounds.
Cells were trypsinized and pelleted at 4, 8, 10, 12, and 24 hr after transfection.
To measure integrated copies, cells were passaged over 10 days in the pres-
ence of 1 mM raltegravir to block viral replication.
Analysis of Next-Generation Sequencing Data
Data were obtained from the Gene Expression Omnibus (GEO) (Edgar et al.,
2002) or the Sequence Read Archive (SRA) (Leinonen et al., 2011) as detailed
in Table S2. Raw sequencing reads were mapped to the GRCh37/hg19 human
genome assembly using the Bowtie2 short read aligner (Langmead and Salz-
berg, 2012). To delineate regions significantly enriched in BRD2–4, we used a
shape-based peak calling approach (Hower et al., 2011) considering an
average fragment length of 150 bp, the size of nucleosomal DNA, and a p value
cutoff of 0.001. Distances from MLV integration or MRC sites to BRD2, -3, -4,
Pol II, H3K4me3, or CpG islands were determined and analyzed (Berry et al.,
2006) using Prism 5.0 (GraphPad software).
Sequence read densities were determined in 10 kb windows around MLV
integration, MRC, or refGene TSSs by counting fragment-length-extended
sequence tags in 50 bp bins for the sample and (when available) control
libraries. The signal density was calculated as the difference between these
two with negative values set to 0, after normalization by total sequencing
depth. MLV and MRC sites were counted according to the same procedure
in 50 bp bins in the studied regions and normalized to the total number of sites.
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